SOURCE: Lattice Biologics Ltd.

Lattice Biologics Ltd.

April 01, 2016 09:00 ET

Lattice Biologics Closes 60% of Private Placement Announced on March 18, 2016

New Funding to Strengthen Balance Sheet and Elevate Production Levels Follows News of Recent Study

SCOTTSDALE, AZ--(Marketwired - April 01, 2016) - Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: BLVKF) ("Lattice Biologics" or the "Company") is pleased to announce that is has closed the first tranche of the non-brokered private placement of special warrants of the Company (the "Special Warrants") announced on March 18, 2016 (the "Offering").

The Company issued 1,326,258 Special Warrants at a price of CDN$0.30 per Special Warrant, representing aggregate gross proceeds of USD $300,000. The net proceeds from the Offering will be used for working capital and general corporate purposes.

Each Special Warrant will automatically convert, without payment of additional consideration and without further action on the part of the subscriber, into Units on May 2, 2016. Each "Unit" consists of one common share in the capital stock of the Company and one-half of one non-transferable common share purchase warrant of the Company (a "Warrant"). Each whole Warrant is exercisable into an additional common share at a price of CDN$0.30 per share for a period of 36 months from the date of closing of the Offering. The Company has the right to increase the size of the Offering without providing further notice to subscribers. Upon the conversion of the Special Warrants into Units, the Special Warrants will be automatically cancelled and will have no further force or effect. The Special Warrants are non-transferable.

The Special Warrants and the common shares and Warrants comprising the Units to be issued upon conversion of the Special Warrants and any common shares issuable upon exercise of the Warrants will be subject to a hold period expiring on August 1, 2016.

Lattice Biologics has received conditional approval from the TSX Venture Exchange for the Offering.

This development provides additional forward momentum for the Company's ongoing efforts to strengthen its balance sheet. This release comes on the heels of the news that Lattice Biologics and the esteemed Sunnybrook Research Institute have partnered to commence a study to develop new cancer screening methods for personalized diagnostics (announced on March 30, 2016).

Lattice Biologics Ltd.

Guy Cook,
Chief Executive Officer
Telephone No: 480-563-0800

About Lattice Biologics Ltd.:

Lattice Biologics recently completed its RTO, becoming a publically traded company on January 4, 2016 and is traded on the TSX-V under the symbol: LBL. The Company is an emerging personalized/precision medicine leader in the field of cellular therapies and tissue engineering, with a focus on bone, skin, and cartilage regeneration.

Lattice Biologics develops and manufactures biologic products to domestic and international markets. Lattice's products are used in a variety of applications, including:

  • Enhancing fusion in spine surgery
  • Enhancing breast reconstruction post mastectomy for breast cancer patients
  • Sports medicine indications, including ACL repair
  • Promotion of bone regeneration in foot and ankle surgery
  • Promotion of skull healing following neurosurgery
  • Enhancing wound repair in burn victims
  • Subchondral bone defect repair in knee and other joint surgeries

Lattice Biologics maintains headquarters, laboratory and manufacturing facilities in Scottsdale, Arizona as well as offices in Toronto Ontario. The facility includes ISO Class 1000 and ISO Class 100 clean rooms, and specialized equipment capable of crafting traditional allografts and precision specialty allografts for various clinical applications.

The Lattice Biologics organization includes a product development and scientific research team of Ph.D.'s, highly trained tissue bank specialists, surgical technicians, certified sterile processing and distribution technicians, and CNC operators who maintain the highest standards of aseptic technique throughout each step of the manufacturing process. From donor acceptance to the final packaging and distribution of finished allografts, Lattice is committed to maintaining the highest standards of allograft quality, innovation, and customer satisfaction.

Lattice Biologics maintains all necessary licensures to process and sell its tissue engineered products within the U.S. and internationally. This includes Certificates to Foreign Governments from the U.S. Food and Drug Administration (FDA) and registrations for 29 countries, which allow the export of bone, tendon, meniscus, ligament, soft tissue, and cartilage products outside of the U.S.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements herein, other than statements of historical fact, are to be considered forward looking. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "continuing", "intends" or variations of such words and phrases or statements that certain actions, events or results "will" occur. Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made and they are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Lattice Biologics to be materially different from those expressed by such forward-looking statements or forward-looking information. Although Lattice Biologics believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

United States Advisory: The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), and may not be offered, sold, or resold in the United States or to, or for the account of or benefit of, a U.S. Person (as such term is defined in Regulation S under the U.S. Securities Act) unless an exemption from the registration requirements of the U.S. Securities Act is available. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in the state in the United States in which such offer, solicitation or sale would be unlawful.

Subscribe to Lattice News Updates

Follow us on Twitter: @LatticeBio

Image Available: http://www.marketwire.com/library/MwGo/2016/4/1/11G091384/Images/Press_Release_040116_LinkedIn_150dpi-c4b77d0b9b8b9cbeab7685ba121a10d9.jpg

Contact Information